Stefan Anker on Muck Rack

Stefan Anker

Heidelberg, Königs Wusterhausen
As seen in: Arthritis & Rheumatology, Color Research & Application, Nature, Wiley, Wiley Online Library, Die Welt, Memory Studies, BMJ Open, JAMA: Journal of the American Medical Association, JAMA Cardiology and
Freier Autor der Welt-Gruppe, Fotograf, verhinderter Rennfahrer, USA-Freund (trotz allem), Bayern-München-aber-nicht-mehr-Uli-Hoeneß-Fan. stefan.anker@welt.de
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Stefan

Contact Stefan, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Finerenone Across Cardiovascular-Kidney-Metabolic Syndrome Stages : Post Hoc Analysis of the FIDELITY Randomized Clinical Trials

|
By Kevin Lo, John W. Ostrominski, Yasuhiro Hamatani, Brian Claggett, Rajiv Agarwal, Stefan Anker, Gerasimos Filippatos, Peter Rossing, Luis M. Ruilope, Bertram Pitt, Alexandros Briasoulis, Kimon Stamatelopoulos, Meike Brinker, Patrick Schloemer, Andrea Glasauer, Scott Solomon , Muthiah Vaduganathan
| JAMA Cardiology
Finerenone Across Cardiovascular-Kidney-Metabolic Syndrome Stages: Post Hoc Analysis of the FIDELITY Randomized Clinical Trials Key Points Question Does cardiovascular-kidney-metabolic (CKM) stage modify the effects of the nonsteroidal mineralocorticoid receptor antagonist finerenone? Findings In this post hoc analysis of 2 phase 3 clinical trials that included 12 990 participants, 3864 (30%) were classified as CKM stage 2, 3275 stage 3 (25%), and 5851 stage 4 (45%).
Open in Who Shared Issue with article?

The microRNA inhibitor CDR132L in patients with reduced left ventricular ejection fraction after myocardial infarction: a randomized phase 2 trial

|
By Johann Bauersachs, Scott Solomon , Stefan Anker, Rudolf de Boer, Gerasimos Filippatos, Tim Friede, Wilfried Hauke, Piotr Ponikowski, Orly Vardeny, Michael Gamborg, Thomas Thum, Isabel Antorrena-Miranda, Rebecca Altschul, Kasper Vinther
| Nature
Abstract MicroRNA-132 (miR-132) is a central regulator of adverse cardiac remodeling. Here we evaluated CDR132L, a synthetic antisense oligonucleotide miR-132 inhibitor, in a multinational, randomized, double-blind, placebo-controlled phase 2 trial (HF-REVERT) in patients with recent myocardial infarction (MI) and left ventricular (LV) systolic dysfunction.
Open in Who Shared Issue with article?

iCARDIO Alliance Global Implementation Guidelines for the Management of Obesity 2025

|
By Stefan Anker, Linong Ji, Tammy Kindel
| Wiley Online Library
1 Preamble The International CARDIO Alliance to Improve Disease Outcomes (iCARDIO Alliance: https://icardioalliance.org) aims to gather leading cardiovascular societies around the globe as partner organisations to improve the quality of cardiovascular care, from prevention and diagnosis to treatment and follow-up.
Open in Who Shared Issue with article?
See all 288 licensed articles (289 Total)

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Get in touch with Stefan

Contact Stefan, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified